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ABSTRACT  
Aim 
To test the effectiveness of a tailored, pharmacist-led centralized advice service to improve 
adherence to patients on established medications. 
Methods 
A parallel group randomised controlled trial was conducted. Patients prescribed at least one 
oral medication for type 2 diabetes and/or lipid regulation were eligible to participate. 677 
patients of a mail-order pharmacy were recruited and randomised (340 intervention, 337 
control). The intervention comprised two tailored telephone consultations with a pharmacist, 
four to six weeks apart, plus a written summary of the discussion and a medicines reminder 
chart. The primary outcome was self-reported adherence to medication at six-month follow-
up, collected via a postal questionnaire, analysed using generalised estimating equations. 
Secondary outcomes included prescription refill adherence, lipid and glycaemic control, and 
patient satisfaction. 
Results 
In intention-to-treat analysis 36/340 (10.6%) of the intervention group were non-adherent 
(<90% of medication taken in the past 7 days) at six months compared to 66/337 (19.6%) in 
the control group, yielding an unadjusted OR of 1.54 (95%CI 1.11-2.15, p=0.01). Analyses of 
dispensing data also showed that the odds of being classified as adherent (≥90%) were 60% 
greater for the intervention group compared to the control group (OR 1.60, 95%CI 1.14-2.24, 
p<0.01). In a subsample of patients who provided blood samples, glycemic and lipid control 
did not differ significantly between groups (p=0.06 and p=0.24 respectively) but positive 
trends were observed. Ninety-two per cent of intervention group patients reported that they 
were satisfied with the service overall. 
Conclusion   
A telephone Intervention, led by a pharmacist and tailored to the individuals’ needs, can 
significantly improve medication adherence in patients with long-term conditions, using a 
mail order pharmacy. Further work is needed to confirm a trend toward improved clinical 
outcome. 
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BACKGROUND  
Self-administered medicines play an important role in managing many long-term conditions 
but research suggests that as many as 30 to 50 per cent of patients do not take their 
medicines as prescribed. 1-3 Non-adherence may be unintentional, for example, forgetting to 
take medication, or it may be an intentional decision not to take medicines or to alter the way 
in which it is taken. Non-adherence can have costly outcomes for the individual patient, 
health systems, and society as a whole, and is of particular and growing importance against 
the current backdrop of ageing populations, with rising prevalence of long-term conditions 
and associated increases in the prescription of medicines. In 2003, the World Health 
Organization suggested that innovations to improve treatment adherence may have a 
greater impact on public health than any further developments in specific medical 
treatments. 2 A recent estimate suggests that $269 billion could be saved globally each year 
through better adherence to medicines. 4 However, although a vast literature has 
accumulated over several decades there remains a dearth of good quality conclusive 
evidence on how best to support medication adherence. A recent update of the Cochrane 
systematic review on adherence interventions found that just five out of 17 studies identified 
as having the lowest risk of bias successfully improved both medication adherence and 
clinical outcomes; and no common characteristics associated with successful interventions 
were identified. 5 
Pharmacists increasingly provide a wide variety of interventions to support medication taking 
and there has been a growing body of research evaluating their role. 6 A recent Cochrane 
systematic review on interventions to improve the safe and effective use of medicines 
identified interventions involving pharmacists in medicines management as having some 
evidence of positive impacts on adherence, medication problems and clinical outcomes but 
highlighted the need to strengthen the evidence base. 7  
In line with the approach advocated in the most recent update of the Cochrane systematic 
review of adherence interventions, the ‘Medicines Advice Service’ intervention in this study, 
was adapted and refined from an intervention that had previously shown promise in a proof-
of-concept randomised controlled trial (RCT), and which was subsequently developed from a 
centralized service into a nationally funded service in pharmacies in England, known as the 
New Medicine Service (NMS). 8 9 A recently published large pragmatic randomised 
controlled trial of the NMS reported that this pharmacist-led approach, focusing on 
individuals’ problems and concerns with newly prescribed medicines, significantly improved 
the odds of self-reported adherence ten weeks after initiating the new medicine. 10 The NMS 
intervention was determined to be cost-effective based on economic modelling of the likely 
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health impact of improved adherence in the long term. 10 While new medicines are an 
important target for intervention, they represent a tiny proportion of overall prescriptions 
within long-term conditions. A recent study found that just 0.25% of prescription items are 
eligible for the NMS.11 Patients’ experiences of problems, concerns and information needs 
are not restricted to new medicines, and research has found that adherence tends to drop off 
over time. 12 13 The aim of this study was to examine the effectiveness of this relatively brief 
intervention in patients already established on long-term medications for diabetes and/or 
lipid regulation, who use mail order pharmacy services. 
METHODS  
Study design 
The Medicines Advice Service Evaluation (MASE) was a single-site parallel group RCT of an 
intervention designed to improve medication adherence. The study was approved by the 
London Brent Research Ethics Committee (12/LO/1657) and the NHS Leeds R&D Office 
(L001_22_11_12_0000). Patients gave written informed consent prior to participation by 
returning a signed consent form by post to the lead author. The study took place between 
December 2012 and September 2014. 
Setting and participants 
Patients prescribed at least one oral medication for type two diabetes and/or lipid regulation 
were recruited through ‘Pharmacy2U’, a UK NHS-contracted Internet and mail order 
pharmacy which has over 300,000 registered patients and works with over 2,000 GP 
practices throughout England. Exclusion criteria included being under the age of 18, living 
outside of England, difficulty reading or understanding English or understanding the details 
of the study, prescribed drugs for dementia or showing signs of cognitive impairment, 
substantial hearing or sight impairment, having medications ordered by a caregiver/family 
member, or receiving a first prescription of a medication included in the study. Eligible 
patients, identified through electronic searches of the pharmacy’s database, were posted an 
invitation letter and information booklet by the pharmacy.  
Randomisation and concealment 
Participants were randomly allocated, in blocks of four, to either the intervention or control 
group, using a 1:1 ratio. Block randomization was used to help ensure a balanced workload 
for the intervention pharmacist as participants were recruited over time. A random number 
sequence was computer generated by [4th author], and [1st author] used the sequence to 
assign participants to a group in the order in which baseline questionnaires were returned. 
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Neither author had any role in the delivery of the intervention. Due to the nature of the 
intervention it was not feasible to blind participants or pharmacy staff to the patients’ 
allocated group. To minimise potential reporting bias, the purpose of the study was 
presented as an opportunity to access advice from a pharmacist to address any issues 
associated with their medications, and did not refer to the concept of adherence. 
Medicines Advice Service Intervention 
The Medicines Advice Service intervention is a pharmacist-led service, designed to be 
modifiable to support patients taking prescribed medication(s) for any long-term condition. In 
this study, the intervention was focussed on lipid-lowering and anti-diabetic medications. A 
report by the IMS Institute for Healthcare Informatics identified diabetes mellitus and 
hyperlipidaemia as having the highest avoidable costs within the US healthcare system. 14 
Both are significant risk factors for cardiovascular diseases, the most common cause of 
deaths from non-communicable disease worldwide, and are the leading contributors to the 
global disease burden in older people. 15 16 Research suggests adherence to these drugs is 
poor and they were therefore considered important to target in this intervention study. 17 18 
The original intervention evaluated by Clifford et al. and used in the NMS is described in the 
online appendix, along with the rationale for adaptations used in this study. 8,10 The 
Medicines Advice Service intervention was comprised of three main components:  
 Two telephone consultations with a pharmacist, four to six weeks apart 
 A written summary of the discussion, posted to the patient after the first consultation 
 A medicines reminder chart, posted to the patient after the first consultation. 
The telephone consultations followed a semi-structured condition-specific interview guide. 
Consultations aimed to identify any particular problems or concerns that the patient may be 
having. Although consultations were designed to specifically target issues related to 
medication adherence and the interview guide was designed to focus on the medicines used 
in the selection criteria, the emphasis could be tailored to individuals’ specific needs, and a 
holistic approach was encouraged, taking into account any other prescribed or over-the-
counter medications, or co-morbid conditions. The pharmacist recorded any problems or 
concerns identified, and interventions provided, on a specially designed page on the 
pharmacy database. If the patient identified no particular issues, the pharmacist reinforced 
the importance of continuing to adhere to the prescribed medication regimen and offered 
healthy living advice (e.g. dietary, weight loss, smoking cessation, etc). The follow-up phone 
call offered an opportunity to review any issues discussed in the initial consultation and to 
identify any new or outstanding problems to be addressed. At the end of the telephone 
consultation each participant was posted a letter summarizing the key points discussed, and 
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a personalized list of their current prescribed medications, known as a medicines reminder 
chart, indicating what each medicine is for, and how much of, and when, each should be 
taken. 19  
Standard care 
Participants in the control group continued to receive their existing dispensing service, 
ordering prescribed medications online or by telephone, and having prescriptions delivered 
to their address. Patients ordering by telephone speak to customer care staff, although there 
were no restrictions on their ability to contact the pharmacist if they wished to. The pharmacy 
does not provide automatic refills but does operate a refill reminder service where patients 
are contacted by pharmacy staff when their repeat prescription is due for renewal and they 
can arrange for the prescription to be approved by the doctor and dispensed. Participants 
who had previously signed up to this service continued to do so, regardless of their group 
allocation. Participants in both groups continued to be treated according to the clinical 
discretion of their general practitioner (GP), hospital specialists or other healthcare 
professional. No formal arrangements were made to contact other healthcare providers 
about the trial. 
Prior to the start of recruitment, pharmacy staff (including the pharmacist who delivered the 
intervention, and customer care staff who scheduled the intervention appointments) received 
training on the background and rationale for the study, the implementation of the study 
protocol, and the intervention and control group procedures. One fully qualified pharmacist, 
who had completed postgraduate training in independent and supplementary prescribing, 
delivered the intervention. All intervention calls were audio recorded and a small random 
selection (n=6) were reviewed and discussed within the research team early in the 
intervention phase. The intervention pharmacist subsequently received feedback from the 
research team and had an opportunity to discuss any challenges encountered. Regular 
contact was maintained with pharmacy staff throughout to provide on-going support and to 
resolve any emerging issues. 
Outcome measures and data collection 
Figure 1: Intervention and data collection timeline 
Self-complete postal questionnaires were used to collect data at baseline, and four weeks 
and six months after the follow up telephone consultation (Figure 1). Questionnaires were 
sent with a freepost return envelope, and a reminder letter was sent if the questionnaire was 
unreturned after 2-3 weeks. Biomedical data was collected at baseline and six month follow-
up. Additional data extracted from pharmacy records included age, gender, number of items 
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on repeat prescription, use of repeat prescription reminder service, and medications 
dispensed. The primary outcome was self-reported adherence to lipid-lowering and/or oral 
diabetes medication(s), measured using questions from the Diagnostic Adherence to 
Medication Scale (DAMS). 20 This short scale was developed following a systematic review 
of self-report adherence measures to address some of the gaps in existing measures. 21 
Content, face and preliminary construct validity has been established in a sample of one 
hundred primary care patients taking a range of medicines for various conditions. Adherence 
ratings on the DAMS have been found to correlate with previously validated self-report 
measures. 20 This instrument records the amount of each medication prescribed, and 
participants were asked to report how much of each they missed in the previous seven days, 
to allow calculation of an adherence rate, either for one medicine individually or overall. The 
DAMS also includes a question to determine if any non-adherence reported is intentional, 
unintentional or both. Questions about taking too much medication were not included in this 
study. In the absence of a gold-standard measure of adherence, a multi-method approach, 
including a self-report and another more objective measure, has been recommended. 2 
Therefore, we also included a measure of refill adherence. A medication possession ratio 
(MPR) was calculated from electronic pharmacy dispensing data. For each anti-diabetes and 
lipid-lowering drug, the sum of the days’ supply was calculated from an index date to a final 
follow-up point (31 August 2014), and divided by the number of days within that range. For 
the control group, the index date was the first dispensing date after consent was received. 
For the intervention group, it was the date the first refill was dispensed after the first 
intervention phone call. Any day’s supply dispensed for any period beyond the final follow up 
was discounted when calculating the MPR. If a participant stopped or changed a medication 
it was censored from the last refill date. Maximum adherence was capped at 100%, even if a 
patient was dispensed more of a drug than they had been instructed to take. 
Participants were also asked to provide an optional blood sample at baseline and six month 
follow-up, using a self-administered finger prick test. Samples were posted to a central 
accredited laboratory where they were analysed. HbA1c was measured by a high-
performance liquid chromatography utilising a cation exchange column. Total cholesterol 
was measured using enzymatic colorimetric methods. 
On a four week follow-up self-report questionnaire, participants in the intervention group 
were asked to rate their agreement with the statement “Overall, I was satisfied with the 
Medicines Advice Service” on a 7-point Likert scale (1=very strongly agree, 7=very strongly 
disagree). 
Data on the length of consultation calls was accessed from audio recordings. A random 
sample of ten per cent of pharmacy consultation records (n=31) were also accessed and 
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analysed descriptively to explore the content of the intervention and possible mechanisms of 
action. 
Sample size and statistical analysis 
Based on a similar pharmacy intervention study, a sample size calculation was carried out 
estimating a reduction in the proportion of patients who self-report non-adherence from 15% 
to 7.5%. 8 With 80% power and a two-sided significance level of 0.05, the required sample 
size was determined to be 278 participants in each group. Assuming a ten per cent dropout, 
we aimed to recruit approximately 612 individuals. 
Adherence data is typically highly positively skewed and therefore both the self-report and 
refill adherence data were dichotomised using a threshold of 90%. This cut point was chosen 
as it is inclusive in detecting non-adherence and has also been found to be significantly 
associated with health outcomes. 23 24 
The primary analysis was performed according to the intention-to-treat principle to minimise 
potential bias from missing responses. Multiple imputation, using the fully conditional 
specification method, was used and twenty complete imputed data sets were created. The 
imputation model included the primary outcome (self-reported non-adherence at four weeks 
and six months post-intervention), which was missing for 15.5% and 19.2% of the sample, 
respectively. Other variables included had no more than 4% missing data. The online 
appendix provides further details on the handling of missing values. Generalised estimating 
equations (GEE) analyses were performed. There were no differences in adjusted GEE 
analyses (adjusted for age, gender, therapeutic group, number of prescription items, 
reminder service, baseline adherence), therefore only unadjusted analyses are presented 
here. 
In secondary analyses, Chi-squared tests were also used to compare the proportion of 
adherent and non-adherent individuals between the intervention and control groups at single 
time points (four weeks and six months). Logistic regression was used to determine the odds 
of adherence in each group compared to the other. Participants were also categorised 
according to whether or not they met guideline recommended targets for cholesterol and 
HbA1c levels, and Chi-squared tests were used to detect any significant differences between 
groups. All analyses were carried out using SPSS version 21 25, and all statistical tests were 
two-sided adopting a 0.05 significance level. 
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RESULTS 
Participants 
A total of 785 patients (17.8%) agreed to participate in the study by returning a signed 
consent form. At baseline, 684 patients were eligible and returned a completed 
questionnaire. Seven were excluded or withdrew prior to randomisation, leaving 340 in the 
intervention group and 337 in the control group. The flow of participants through the study is 
outlined in Figure 2. Table 1 presents the baseline characteristics of the 677 participants 
who were randomised. The intervention and control groups were similar in terms of all socio-
demographic, clinical and medication-related variables measured at baseline.  
Figure 2: Flow of participants through the study 
Delivery of the intervention  
Ninety two per cent of the intervention group (n=310) completed the intervention. Eighteen 
people (5%) did not receive either telephone consultation, and a further twelve received the 
first telephone consultation but did not complete the follow-up consultation. The most 
common reasons for non-completion were not answering multiple calls and/or responding to 
messages to arrange an appointment, and not answering at the time of the appointment. 
Several attempts were made to contact participants and to reschedule missed appointments. 
Initial consultation calls lasted a median of 16 minutes 40 seconds (IQR 13-22 minutes). The 
median length of the follow up consultations was 5 minutes 36 seconds (IQR 3-8 minutes). 
The median length of time between consultations was 35 days (IQR 28-41 days). 
Content of the intervention 
Of 31 randomly selected cases for which pharmacy records were accessed, 26 were 
consultations for cholesterol medicines only, one was for a consultation related to diabetes 
medication only, and four consultations related to both cholesterol and diabetes medicines. 
In two thirds of the first consultation calls sampled, the pharmacist recorded no problems, 
concerns or information needs. For the remaining 10 participants, 23 issues were recorded. 
The most common problem recorded was a potential side effect (n=7, 22.6%), followed by a 
need for more information about medicines (n=4, 13.3%). Table 2 illustrates some examples 
of the types of issues and outcomes recorded by the pharmacist during consultations. 
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Table 1 - Baseline characteristics of participants 
Data are number (%) unless otherwise stated. SD=Standard deviation, IQR=Interquartile range. 
1 missing=2, 2 missing=23, 3 missing=3, 4 missing =5, 5 missing=7, 6 includes one postal reminder, 7 missing=16, 8 
n=284, 9, n=97. 
 
 
Participant characteristics Intervention 
n=340  
Control 
n=337 
Age in years (mean, SD) 69.9 (9.2) 69.9 (10.1) 
Gender (Female) 133 (39.1) 148 (43.9) 
Marital status1   
Single, never married 22 (6.5) 24 (7.2) 
Married/civil partnership/living with partner 228 (67.1) 210 (62.7) 
Widowed 54 (15.9) 64 (19.1) 
Separated or divorced 36 (10.6) 37 (11.0) 
Living alone1 92 (27.1) 98 (29.3) 
Education2   
Primary school or no formal education 53 (16.0) 51 (15.8) 
Lower secondary level (e.g. GCSE/O Level or equivalent) 57 (17.2) 73 (22.6) 
Upper secondary level (e.g. A-levels/Highers or equivalent) 32 (9.7) 35 (10.8) 
Other qualifications below degree level (e.g. vocational 
qualifications) 
91 (27.5) 87 (26.9) 
Degree or higher degree 98 (29.6) 77 (23.8) 
English as first language3 328 (96.8) 328 (97.9) 
Ethnicity (White)4 324 (95.9) 325 (97.3) 
Employment status4   
Employed/Self-employed 60 (17.8) 69 (20.7) 
Retired 267 (79.0) 246 (73.7) 
Full-time home-maker / carer / unemployed / disabled or too ill to 
work 
11 (3.3) 19 (5.7) 
Self-reported general health5   
Excellent 27 (8.0) 31 (9.3) 
Very good 82 (24.3) 91 (27.3) 
Good 131 (38.9) 123 (36.9) 
Fair 79 (23.4) 69 (20.7) 
Poor 18 (5.3) 19 (5.7) 
Therapeutic group   
Hyperlipidaemia 261 (76.8) 253 (75.1) 
Type 2 diabetes 14 (4.1) 18 (5.3) 
Both hyperlipidaemia and type 2 diabetes 65 (19.1) 66 (19.6) 
Prescription reminder service   
Telephone reminder 155 (45.6) 175 (51.9) 
Email reminder6 101 (29.7) 90 (26.7) 
No reminder 84 (24.7) 72 (21.4) 
Exemption from prescription payment3 329 (97.1) 315 (94.0) 
Total number of items on repeat prescription list (median, IQR) 6.00 (5) 6.00 (5) 
Total number of cholesterol and/or diabetes medications 
prescribed  
  
1 258 (75.9) 260 (77.2) 
2 51 (15.0) 52 (15.4) 
3 20 (5.9) 17 (5.0) 
4  9 (2.6) 7 (2.1) 
5 2 (0.6) 1 (0.3) 
Self-reported adherence to lipid-lowering and/or diabetes 
medication in the previous seven days (Diagnostic Adherence to 
Medication Scale)7 
  
Median (IQR) 100 (0) 100 (0) 
<90% adherence 44 (13.3) 43 (13.1) 
Patients meeting guideline targets   
Total cholesterol <5mmol/L8 86 (56.2) 82 (62.6) 
Glycated haemoglobin (HbA1c) <7%9 23 (44.2) 20 (44.4) 
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Table 2 Examples of issues and outcomes extracted from a random sample of pharmacist records of 
telephone consultations   
ID Issues reported by the patient in first 
telephone consultation 
Advice pharmacist recorded 
as given during the first 
telephone consultation 
Outcome reported to 
pharmacist at follow-up 
consultation 
541 Has not been taking atorvastatin for 2-3 
months. Thought they were causing 
insomnia (took at night), and didn't think 
they were doing anything. Also was put 
off by media reports about statins in the 
papers. Decided that he did not want to 
carry on with them. 
Advised him to take the 
atorvastatin in the morning. 
Gave more info about the 
recent statin media stories and 
that the evidence still shows 
they have more benefits than 
risks in most patients. 
Has been taking them daily 
since the first call, and without 
side effects. He is happy with 
this, and is due soon to receive 
the results of his latest 
cholesterol test. 
374 Says that he misses all of his tablets 
(except warfarin) for a day, around once 
a month, intentionally (if he gets a 
headache etc) as a kind of 'detox'.  
Advised that this was not 
necessary. 
He has taken the tablets without 
stopping since the first call. 
111 Had side effects with simvastatin; 
changed to atorvastatin; side effects not 
as bad, but still takes infrequently. Only 
takes one tablet once a week (instead of 
once daily).  
Advised to try taking it in the 
morning instead of at night to 
see if this minimises side 
effects. 
See general practitioner (GP) if 
side effects persist - briefly 
discussed alternative options 
e.g. ezetimibe, fibrates.  
Has taken a dose in the 
morning, every single morning 
since our last call. Slight leg 
pain but can "walk this off" and 
is very happy with the 
atorvastatin tablets now and 
intends to continue with it each 
day. 
777 No issues with his simvastatin. But found 
the aspirin tablets were hard to remove 
from packaging sometimes.  
Put note on system for us to 
send these in bottles in future. 
Finds this much easier than 
using the blister packs. 
630 He is taking simvastatin 40mg and also 
Amlodipine (and experiences muscle 
aches and pains) 
Asked him to ask GP if the 
statin should come down to 
20mg as per recent Medicines 
and Healthcare products 
Regulatory Agency guidance 
Found this helpful but has not 
made the appointment with his 
GP yet to discuss this. 
872 Does not have annual check-ups for 
cholesterol/Liver function tests. 
Advised to mention to GP or 
diabetic nurse when next at the 
surgery. 
Has not had the opportunity to 
do this yet but reinforced the 
advice. 
 
Effect of the intervention on self-reported non-adherence 
Both four weeks and six months after intervention the intervention group had significantly 
better self-reported adherence (defined as ≥90% of medication taken in the previous seven 
days) compared to the control group, across all analyses (Table 3). According to the primary 
intention-to-treat GEE analysis, the intervention group had 54% increased odds of being 
adherent compared to the control group (OR 1.54, 95%CI 1.11 to 2.15, p=.010). Complete 
case and available case analyses produced less conservative estimates. The results of 
adjusted and unadjusted logistic regression analyses at four week and six-month follow-ups 
are presented in Table 3. 
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Table 3 Unadjusted and adjusted effect of the intervention on self-reported non-adherence measured 
using the Diagnostic Adherence to Medication Scale at four week and six month follow up 
* OR = Odds Ratio, CI = Confidence Interval 
** No p values are provided for ITT analyses. SPSS does not support doing a Chi-squared test on imputed data 
sets. 
§ Logistic regression adjusted for age, gender, therapeutic group, number of prescription items, reminder service, 
baseline adherence 
1. Available case analysis included all available data at each time point.  
2. Complete case analysis included only those who had questionnaire data available at all three data collection 
points. 
 
Effect of the intervention on pharmacy refill adherence 
Analyses of dispensing data drawn from pharmacy records showed that over a longer follow 
up period, averaging 434 days, 88/294 (29.9%) of the intervention group were categorised 
as non-adherent (<90% of medication available) compared to 127/313 (40.6%) of the control 
group, yielding an odds ratio of 1.60 in favour of the intervention group (95%CI 1.14-2.24, 
p=.006).  
Effect of the intervention on glycaemic and lipid control 
Valid results were obtained from 169 cholesterol tests and 41 HbA1c tests at follow up. Six 
months after intervention, the intervention group had twice the proportion of participants 
achieving HbA1c less than 7% (66.7%, n=16) compared to the control group (31.3%, n=5), 
with this difference approaching statistical significance (p=.061). The proportion of patients 
meeting guideline targets for total cholesterol levels (<5mmol/L) was also higher in the 
intervention group (65.3%, n=64) compared to the control group (55.1%, n=38) at follow up, 
although the differences were not statistically significant (p=0.24). 
 
 
 Chi-squared Logistic Regression Generalised 
Estimating Equations 
Analysis 
Proportion <90% adherent Unadjusted Adjusted§ Unadjusted 
n Intervention Control P  n OR (95% 
CI, p)* 
n OR (95% 
CI, p) 
n OR (95% CI, p) 
Four week follow up 
Intention to 
treat (ITT) 
677 39/340 
(11.5) 
68/337 
(20.2) 
** 677 1.93 (1.22-
3.05, .005) 
677 2.20 (1.33-
3.65, .002) 
 
Available 
cases1 
564 19/270 (7.0) 50/294 
(17.0) 
.000 564 2.71 (1.55-
4.72, .000) 
556 3.53 (1.87-
6.67, .000) 
Complete 
cases2 
494 17/244 (7.0) 39/250 
(15.6) 
.004 494 2.47 (1.35-
4.50, .003)  
494 3.43 (1.72-
6.84, .000) 
Six month follow up 
Intention to 
treat 
677 36/340 
(10.6) 
66/337 
(19.6) 
** 677 2.04 (1.23-
3.40, .006) 
677 2.24 (1.29-
3.88, .004) 
677 1.54 (1.11-2.15, 
.010) 
Available 
cases1 
541 16/270 (5.9) 41/271 
(15.1) 
.001 541 2.83 (1.55-
5.18, .001) 
532 3.40 (1.75-
6.61, .000) 
673 1.82 (1.26-2.61, 
.001) 
Complete 
cases2 
494 14/244 (5.7) 35/250 
(14.0) 
.003 494 2.67 (1.40-
5.11, .003) 
494 3.48 (1.69-
7.15, .001) 
494 1.69 (1.10-2.61, 
.017) 
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Satisfaction with the Medicines Advice Service  
On the whole satisfaction with the Medicines Advice Service was high, with 91.8% (n=245) 
agreeing that they were satisfied overall. Just four participants (1.5%) expressed any 
dissatisfaction with the service. Two did not give a reason for dissatisfaction. One participant 
stated that the service was not really useful as he had no concerns about his medicines and 
one other participant described a problem with the pharmacy’s services in general rather 
than with the Medicines Advice Service in particular. Regression analyses identified no 
significant predictors of overall satisfaction. The majority of participants (81.6%, n=217) 
agreed that they would recommend the service to someone else in their position.  
DISCUSSION 
The MASE RCT has shown that mail order pharmacy patients who participated in a tailored 
intervention delivered by a pharmacist had significantly increased odds of adherence, 
measured using both self report and pharmacy refill data, compared to a usual care control 
group. The findings were robust, producing consistent effects in both intention-to-treat and 
complete case analyses.  
The magnitude of the effect on self-reported adherence in our study is consistent with similar 
community pharmacy-based interventions in a variety of long-term conditions in the UK. 8 10 
26 The study also provides insight into the effect of pharmacist intervention on medication 
refill adherence. Studies using dispensing data are relatively common in the US but this is 
one of the first UK studies to examine adherence based on pharmacy prescription refill rates. 
This approach allows for objective assessment of the effect of the intervention over a 
considerably longer period of time, compared to previous studies. 8 10 The findings indicate 
that this relatively brief intervention can have a sustained impact on adherence. However, 
the proportion of patients classified as non-adherent according to dispensing data was 
higher than indicated in self-report data. It may be that the discrepancy reflects real 
differences in adherence in the time periods each measure covers (7 days compared to 
mean 434 days). Alternatively, social desirability bias in self-report may have resulted in an 
over-estimation of the true level of adherence, and/or refill adherence may be 
underestimated for the one fifth of patients in this study who reported using another 
pharmacy at least once to collect their diabetes or cholesterol drugs. 
Glycemic and lipid control were also assessed as objective markers of clinical impact, and 
non-significant improvements in the proportion of patients meeting guideline targets were 
observed in the intervention group compared to the control group. However, the study used 
a novel method of collecting blood samples at a distance and many patients reported 
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difficulty drawing a sufficient sample of blood using the finger prick testing kit supplied. The 
number of samples available for analysis at follow-up was therefore small and further 
appropriately powered research is required to determine whether these findings are reliable 
and clinically meaningful. Most, though not all, reviews have identified improvements in 
cholesterol and glycaemic levels associated with pharmacist intervention. 27-30 
High rates of intervention completion indicated that the service was also acceptable to 
patients. Data collected on patients’ satisfaction and willingness to recommend the service 
support this view. These findings are largely consistent with other studies looking at patients’ 
perspectives on pharmacist intervention. 31 32 
Strengths and Limitations  
This large randomized controlled trial, incorporating data from multiple sources (patient self 
report, pharmacy records, blood results) and exploring outcomes over considerably longer 
follow up periods, strengthens and extends previous findings on the efficacy of tailored 
pharmacist intervention in improving adherence to long-term medications. However, there 
are a number of limitations. Firstly, although the required sample size was exceeded in this 
trial, a large number of eligible patients were invited to take part, and the positive response 
rate was just over 17%. In order to explore the possibility of recruitment bias, the MASE 
study sample was compared with anonymised data supplied by the pharmacy on four 
variables: age, gender, number of items on repeat prescription and uptake of the pharmacy’s 
repeat prescription reminder service. No major differences were found in the characteristics 
of those who agreed to take part compared to the overall eligible population on these 
variables. 
Although the intervention was developed using the available evidence and theory, and key 
elements had been tested in previous research, these were applied in a novel setting, and 
additional new components and methods of data collection may well have benefitted from a 
feasibility and piloting stage, as recommended in the Medical Research Council guidelines 
on developing and evaluating complex interventions.33 This may have helped to identify 
methods to improve both the initial response rate and the return of viable blood samples. 
Participants were recruited from a single mail-order pharmacy and it is possible the results 
may not be generalizable to other settings. Recent database studies from the US have 
suggested that use of mail-order pharmacy is associated with better refill adherence and 
health outcomes when compared with regular brick and mortar pharmacies. 34 35 Patients in 
the UK are free to obtain their NHS prescriptions from any pharmacy. No published research 
has explored the characteristics of patients who opt to use mail-order pharmacy. A 
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comparison of our baseline demographic and clinical data with other UK studies suggests 
that patients who use mail order pharmacy in the UK may not differ significantly from those 
using regular community pharmacy services. 8 10 36-38 
A third limitation linked to generalizability, was the delivery of the intervention by just one 
pharmacist, who holds a postgraduate qualification in independent and supplementary 
prescribing, and may have been particularly motivated and enabled to consistently and 
rigorously deliver the intervention. Further testing of the intervention with a wider group of 
pharmacists would be beneficial. However, the widespread implementation of similar 
services such as the NMS and Medicines Use Reviews (MUR) in community pharmacies, 
suggests that this type of intervention is transferable to different settings and pharmacists. 
Implications for practice and future research 
To the best of our knowledge this is the first UK study to explore the impact of pharmacist 
intervention in a cohort of patients using mail-order pharmacy. Internet and mail order 
pharmacy is a relatively new phenomenon in the UK and represents a small but growing 
proportion of pharmacies.39 The results of this trial demonstrate that it is both feasible and 
effective to provide adherence support to mail-order pharmacy users, using a combination of 
telephone consultations and written information. Further research is needed to establish cost 
effectiveness in the mail order setting. Previous work with similar interventions suggests that 
this is a cost effective approach, with improvements in adherence translating into modest 
healthcare gains and cost savings in the long term. 9 10 Although the mail order context has 
some unique characteristics, parallels between this intervention and existing services such 
as the NMS suggest that this approach could be feasibly implemented within community 
pharmacy settings, or that these services could be extended and adapted to better facilitate 
mail order pharmacies. Indeed, evidence from the evaluation of the NMS, along with findings 
from the PharmOutcomes database indicates that even in a community pharmacy setting 
telephone consultations are considered convenient and appropriate, with the majority of 
NMS interventions delivered by telephone. 10 40 41  
CONCLUSION 
The results presented here have shown that tailored intervention, delivered by a pharmacist, 
comprising both spoken information and advice by phone and written information by post, 
was acceptable to patients, and was effective in significantly improving medication 
adherence in a mail-order pharmacy cohort. These results are robust, using two methods of 
measuring adherence, and the effect is still present more than six months after the 
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intervention. The findings provide further support for the enhanced role of pharmacists in 
supporting and advising patients with their medicines to improve outcomes.  
 
Footnotes 
Trial registration Clinicaltrials.gov NCT01864239, 29 April 2013. The trial protocol can be 
accessed in the online appendix. 
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